8月13日 - ** 基因医疗公司 MeiraGTx(MGTX.O)股价上涨 6%,至 13.74 美元
** 该公司报告第二季度营收为3.2143亿美元,其中包括2.046亿美元的许可收入。去年同期未产生许可收入
** 许可收入源于MeiraGTx的专有基因治疗递送平台,该平台可实现精准的小剂量脑部输注,并已授权给Reogen Limited用于开发以神经系统疾病为重点的疗法,包括帕金森病
** 计入本交易日涨幅后,MGTX股价年内累计上涨73%
8月13日 - ** 基因医疗公司 MeiraGTx(MGTX.O)股价上涨 6%,至 13.74 美元
** 该公司报告第二季度营收为3.2143亿美元,其中包括2.046亿美元的许可收入。去年同期未产生许可收入
** 许可收入源于MeiraGTx的专有基因治疗递送平台,该平台可实现精准的小剂量脑部输注,并已授权给Reogen Limited用于开发以神经系统疾病为重点的疗法,包括帕金森病
** 计入本交易日涨幅后,MGTX股价年内累计上涨73%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.